BioSpace News Archive

Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc.

Sermonix Pharmaceuticals Inc. today announced that its lead drug candidate, lasofoxifene, improved vaginal/vulvar symptoms while fulvestrant worsened them in a study of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced the appointment of Howard J. Franklin, MD, as Senior Vice President, Medical.

Royal Philips announced the presentation of various clinical study results at this year’s Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event that confirm Philips’ commitment to clinically validating its innovations in cardiac and cardiovascular care.

Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry and GI Reviewers, LLC Gastroenterology consultants and central readers, together with RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today announced their new AI-based scoring system for inflammatory bowel diseases.

Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data.

Revelation Biosciences Inc. announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

Therapeutic Solutions International (TSOI) announced today plans to initiate ten patient proof-of-concept clinical trial aimed at demonstrating the ability of FloraStilbene™ to stimulate the immune system in advanced breast cancer patients.

Metagenomi announced that it will participate in two upcoming investor conferences.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.